Pathios Therapeutics Ltd.
https://pathiostherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pathios Therapeutics Ltd.
ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach
Emerging Company Profile: Backed by $20m in seed funding, the UK firm is going against the grain by antagonizing, instead of agonizing, G protein-coupled receptor 35 with an eye to treating colorectal cancer and other gastrointestinal conditions.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice